Anavex Life Sciences Corp. announced new precision medicine clinical data from its Phase IIb/III Alzheimer's disease trial, demonstrating oral blarcamesine cognitive resilience results approximating normal aging. After 48 weeks, the defined Precision Medicine population ABCLEAR3, consisting of early AD patients with confirmed and progressed pathology taking 30 mg once-daily oral blarcamesine, showed barely detectable decline.
This cognitive outcome was comparable to minimally perceptible decline observed in prodromal (pre-dementia) aging adults, despite the more advanced stage of AD impairment at baseline in the blarcamesine population. The respective placebo group in the ANAVEX2-73-AD-004 Phase IIb/III ABCLEAR3 population declined by 5.592 points on ADAS-Cog13, resulting in an ADAS-Cog13 LS mean difference of -4.739 (P=0.0004) versus blarcamesine.
This represents an 84.7% reduction in decline at 48 weeks of blarcamesine treatment versus placebo on the cognitive endpoint ADAS-Cog13. The company believes blarcamesine could represent a novel treatment option for up to approximately 70% of early Alzheimer’s patients, offering unprecedented cognitive stabilization and potentially transforming Alzheimer’s care through individualized, tailored therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.